Previous 10 | Next 10 |
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on multiple discriminant analysis ((MDA)) breakout selections over more than five years. This subset of the different portfolios I regularly analyze has now reached 135 weeks of public selections as part of t...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 134 weeks of public selections as part of this ongoing live forward-testing. In...
DUBLIN, Ireland, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, announced today the appointment of Oleg Nodelman to its Board of Directors. “Oleg is a veteran biotechnology investor and advisor with deep roots in th...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than five years. This subset of the different portfolios I regularly analyze has now reached 133 weeks of public selections as part of this ongoing live forward-testing. ...
Thinly traded micro cap Prothena ( PRTA +8.4% ) is up on below-average volume on the heels of an upgrade to Outperform at Evercore ISI citing its healthy cash position ($390.3M at the end of September) and the potential of its TTR antibody program. More news on: Prothena Corporation plc,...
Agenus (NASDAQ: AGEN ) resumed with Buy rating and $6 (36% upside) price target at B. Riley FBR. Shares up 1% premarket. More news on: Agenus Inc., Cabaletta Bio, Inc., Geron Corporation, Healthcare stocks news, Stocks on the move, , Read more ...
Prothena (NASDAQ: PRTA ): Q3 GAAP EPS of -$0.49 beats by $0.02 . More news on: Prothena Corporation plc, Earnings news and commentary, Healthcare stocks news, Read more ...
Net cash used in operating and investing activities was $9.2 million in the third quarter and $38.9 million for the first nine months of 2019; quarter-end cash and restricted cash position of $393.0 million provides funding to advance a diversified neuroscience pipeline DUBLIN, Ire...
DUBLIN, Ireland, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical-stage neuroscience company, will announce financial results for the third quarter and first nine months of 2019 on November 5, 2019 after the close of the U.S. financial markets. Consistent...
Gainers: BNED +7.6% . DPW +5.0% . RMNI +3.9% . OTCQB:KSHB +3.6%. BCOV +3.4% . More news on: Barnes & Noble Education, Inc., DPW Holdings, Inc., Rimini Street, Inc., Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Prothena Corporation plc Company Name:
PRTA Stock Symbol:
NASDAQ Market:
Prothena Corporation plc Website:
2024-07-03 23:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-02 10:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Prothena to receive $80 million from Bristol Myers Squibb for exclusive global license to PRX019, a potential treatment of neurodegenerative diseases with an undisclosed target Prothena will initiate a Phase 1 clinical trial for PRX019 in 2024 Prothena Corporation plc (NASDAQ:PRTA),...